In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Introduction:The temporal relationship between smoking exposure and bladder cancer (BC) diagnosis remains ill defined. This study aims to cross-correlate and temporally associate changes in US…
The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.
Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Submit research in oncology to be considered for EMUC23. Topics include prostate cancer, bladder cancer, RCC, testicular and penile cancers.
BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Apply now for STEPS Meet-the-Expert Session! Elevate your oncological urology expertise, connect with experts, and shape the future of scientific research.
Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.
INTRODUCTION AND OBJECTIVE:High health costs in the United States prompted health insurance companies to turn to prior authorization (PA) to reduce costs. While useful from…
